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HUMAN HERPESVIRUS 8 CAN BE TRANSMITTED THROUGH BLOOD IN DRUG ADDICTS
CARLOS SOSA1,  3, JORGE BENETUCCI2, COLLEEN HANNA1, LAURA SIECZKOWSKI1, GABRIEL DELUCHI2,
ANA MARIA CANIZAL2, HAMAKWA MANTINA1, WINSLOW KLASKALA3, MARIANNA BAUM3, CHARLES WOOD1
1
 University of Nebraska School of Biological Sciences, Lincoln NE USA; 2 Fundación de Ayuda al Inmunodeficiente, FUNDAI,
Buenos Aires, Argentina; 3 University of Miami School of Medicine, Fogarty International Center, Miami, FL, USA
Abstract Human Herpes virus type-8 (HHV-8) seroprevalence was studied in a population of HIV positive intra-
venous drug users (IVDUs) from Argentina.  Analysis of this population also indirectly made it possible
to study HHV-8 blood transmission, because these individuals frequently engage in needle sharing behavior and
are capable of acquiring a broad array of blood borne pathogens, including Hepatitis B/C virus. The seroprevalence
of HHV-8 in IVDUs was compared to a group of non-IVDUs and HIV negative individuals. Of the 223 individuals
tested, 13.45% were HHV-8 positive, 16.99% in the IVDUs group, and 5.71% in the non-IVDUs. Among HIV positive
IVDUs, 25/144 (17.36%) were also HHV-8 seropositive. The seropositivity rate of HHV-8 in HIV negative IVDUs
was 11.1%.  In contrast, HHV-8 seroprevalence in HIV negative heterosexual individuals without drug usage behavior
was even lower (5.71%). The rate of HHV-8 infection in HIV positive IVDUs was three times as high compared to
the non IVDU HIV negative individuals, suggesting that IVDU is a risk for HHV-8 infection. Furthermore, it was found
that IVDUs showed a very high rate of Hepatitis B/C (52.77%), which also correlate with HHV-8 infection in this
population (23.68%). All Hepatitis B/C positive individuals were also HIV positive. Our data confirm other studies
showing that individuals who share needles are at risk for acquiring Hepatitis B/C and HIV infections. In addition,
our results suggest that they are also at risk to acquiring HHV-8 infection by the same route.
Keywords: HIV, HHV-8, IVDU, hepatitis, seroprevalence
Resumen El virus Herpes humano 8 puede transmitirse por sangre en adictos a drogas endovenosas. Se
estudió, en la Argentina, la seroprevalencia de HHV-8 en adictos a drogas intravenosas (ADIV) HIV
positivos. Este análisis también permitió evaluar, en forma indirecta, la posibilidad de transmisión del HHV-8 por la
sangre, debido a que estas personas tienen la costumbre de compartir las agujas, y de esta forma pueden adquirir
una amplia cantidad de patógenos que transporta la sangre, inclusive los virus de la Hepatitis B y C. La
seroprevalencia del HHV-8 en los ADIV fue comparada con un grupo de individuos no ADIV y HIV  negativos. Del
total de 223 muestras analizadas, el 13.45% eran HHV-8 positivas; el 16.99% considerando solo los ADIV (153), y
el 5.71% de los no ADIV(70). Entre los ADIV HIV  positivos, 25/144 (17.36%) eran también HHV-8 positivos. El
porcentaje de seropositividad de HHV-8 en los ADIV HIV  negativos fue del 11.1% (1/9). A diferencia de esto, el
porcentaje de seroprevalencia del HHV-8 en individuos heterosexuales, HIV  negativos y sin antecedentes de haber
utilizado drogas, fue inclusive más bajo (5.71%). El porcentaje de infección por HHV-8 en personas ADIV HIV
positivas fue más del doble comparado con aquellos individuos no ADIV HIV  negativos, demostrando que el compartir
agujas es un riesgo de infección del HHV-8. Además, se halló que los ADIV presentaban un alto porcentaje de
Hepatitis B y C (52.77%), lo cual, en esta población, está también relacionado con la infección por HHV-8 (23.68%).
Todos los individuos con Hepatitis B y C, eran a la vez HIV  positivos. Nuestra información confirma otros estudios
que muestran que aquellas personas que comparten agujas, corren el riesgo de adquirir Hepatitis B, C y HIV.
Además, nuestros resultados sugieren que, por la misma vía, pueden adquirir el HHV-8.
confirmed until Chang and coworkers discovered HHV-8
in 19941.
Despite recent intensive studies, the route of
transmission of HHV-8 is still not well understood.
Abundant epidemiological and serological studies have
indicated a sexual transmission2,3.  However, sexual
transmission alone does not explain the ample distribution
of HHV-8 in some areas of the world; for example in
some regions of Africa and Italy, where high HHV-8
seroprevalence has been observed4.
In addition to HHV-8 sexual transmission, the
possibility of blood transmission may exist. Although the
HHV-8 has been associated with all clinical forms of
Kaposi’s sarcoma (KS), with pleural effusion lymphomas
(PEL) and with Castleman’s disease. For a long time,
researchers have suspected that an infectious agent
could cause KS. Different viruses have been suspected
to be associated with the disease, but none was
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virus can be found in blood during viremic stages of HHV-
8 disease5, the transmission through blood is still
controversial and has not been studied extensively.
Lennette and coworkers have reported a low HHV-8
seroprevalence rate among American IVDUs, but the
study group was very small and the results could be
biased by the geographical distribution and the size of
the population6. Other groups have also published limited
data and found only a 3.17% HHV-8 seroprevalence in a
small group of Edinburgh intravenous drug users
(IVDUs)7. However, the risk of HHV-8 transmission by
blood transfusion has been demonstrated by Blackbourn
et al8. They studied a group of blood donors and found
one (out of 72 studied) who was consistently positive for
HHV-8 after phorbol ester stimulation of his peripheral
blood monocyte cells (PBMCs) by RT-PCR. Despite this
report, the study of seroprevalence rates for HHV-8 in a
large group of IVDUs has not been reported.  IVDUs are
an ideal population to study parenteral transmission
because these individuals usually share contaminated
needles, enabling a vast array of blood borne pathogens,
such as hepatitis B/C virus and HIV, to be passed from
one infected person to another.  Therefore, the aim of
this work was to study HHV-8 seroprevalence as well as
to assess the risk of parenteral transmission by needle
sharing in a population of HIV positive IVDUs, from a
period of 1994 to 1997 in patients from Buenos Aires,
Argentina.
Patients and Methods
This work was a retrospective study on HIV and HHV-8 infection
performed by the University of Nebraska school of Biological
Sciences and the University of Buenos Aires School of
Medicine.  A total of 223 men and women were enrolled in the
study. A group of 223 patients with a median age of 28.3 years
were studied.  They were 96.13% men and 3.87% women. The
majority of the individuals included in the study had less than
ten years of formal education and also were of low socio-
economic status.  Of all individuals, 56% were from Buenos
Aires province and 44% were from the Buenos Aires city. The
patients attended clinics at FUNDAI, a non-governmental
organization to help AIDS patients, in Buenos Aires city in
Argentina. The clinics at FUNDAI provide free HIV testing as
well as counseling to the general population. Participants were
included in two groups.  The first group consisted of 153 male
and female HIV positive IVDUs at different stages of AIDS, and
the second group consisting of 70 HIV non IVDUs heterosexual
negative men and women. Patients attended the clinics between
1994 and 1997, when they were tested for HIV and the leftover
sera stored. All eligible participants were included in the study,
however, subjects who attended the clinics more than once
were not re- enrolled in the study. All participants signed
informed consent forms. Information was gathered by an
interview at the time of visit and a questionnaire was
administered to obtain socio-demographic information on HIV
risk factors. Individuals who gave informed consent were tested
for HIV at the FUNDAI laboratory by ELISA and Western Blot.
Patients with HIV received counseling at the clinics.  HHV-8
testing was not available at the clinics at that time, so
information about the HHV-8 serostatus was not given to the
patients.
Samples were first screened by an in-house IFA, using tetra
decanoyl phorbol acetate (TPA) stimulated cell line.  Positive
samples were further confirmed by a commercial IFA assay,
samples were blindly tested by independent lab technicians.
In-house Immunofluorescence Assay (IFA) to detect human
HHV-8 antibodies. This technique was based on a report by
Lennette et al6, with minor modifications and was carried out
using an HHV-8 positive cell line (BCBL-1) (from Dr. Ganem
via the AIDS Repository Program), as a source of antigen. An
HHV-8 negative cell line (BJAB), and an EBV producer cell line
(P3HR-1) were used as controls.  Cells were induced with 20
ng/ml of TPA for three days and spotted (20,000 cells) onto
specially designed IFA slides (Erie Scientific). Cells were air
dried inside the laminar hood and then fixed with ice cold
acetone for ten minutes.  Slides were then washed once in PBS
and dried for IFA.  Serum samples diluted in PBS were applied
to individual wells on the slide and incubated for 30 min at 37
°C in a humid chamber. Two washes in PBS were performed
to eliminate nonspecific binding, and an anti-human IgG1,2,3
monoclonal antibody (ATCC HF6508) was added to the wells
and incubated at 37 °C in the humid chamber for another 30
min. After that, two more washes of PBS were performed and
an anti-mouse FITC conjugate was added (Lampire
Laboratories). Incubation in a humid chamber at 37 °C was
carried out for 30 min, followed by two more washes in PBS.
Finally, the slides were counter-stained with 0.05% Evans Blue,
and mounted in a solution of PBS/glycerol (Sigma). Samples
were examined using an epifluorescent Olympus BX60
microscope.  All samples were coded and an inverse antibody
titer of 10 or more against HHV-8 infected BCBL-1 but not
against BJAB cells was considered positive.
All positive samples were confirmed using a commercial
HHV-8 IFA kit (kindly provided by Dr. D. Ablashi, ABI). The
assay was carried out according to manufacture’s protocol.
Results
In order to study the risk of parenteral transmission, two
groups of individuals were tested.  The first group
contained 153 IVDUs, the great majority (144/153) were
HIV positive; and the second group consisted of 70 non
IVDUS HIV negative heterosexual individuals.  The HHV-
8 seroprevalence rates between these two groups were
compared.
Of the 223 individual tested, 30 (13.45%) were found
to be HHV-8 positive, 26/153 (16.99%) in the IVDU
population, and 4/70 (5.71%) in the non IVDU group
(Table1). Among the HIV positive IVDUs, 25/144
(17.36%) were also HHV-8 positive. There were very few
HIV negative individuals in our IVDU population, only 9/
153 (5.88%).  Among these nine only one patient was
seropositive for HHV-8 (11.1%). In contrast, the HHV-8
seroprevalence in HIV negative heterosexual individuals
without drug usage behavior was even lower, 4/70
(5.71%). Interestingly, the rate of HHV-8 infection in HIV
positive IVDUs was almost three times as high when
compared to the HIV negative individuals (17.36% vs.
5.71%), suggesting that intravenous drug usage is a risk
for HHV-8 infection (O.R=3.37; X 2 = 4.32, p = 0.05).
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TABLE 1.– Human Herpesvirus 8 positive samples in selected populations
n HIV positive HHV-8 Positive HIV+/ HHV-8 Positive
IVDUs 144/153 (94.11)+ 26/153 (16.99) 25/153 (16.33)
153
Non-IVDUs  0/70 4/70 (5.71) 0/70
70
Total Study 144/223 (64.58) 30/223 (13.45) 25/223 (11.21)
223
+Percent of seropositivity
We next analyzed the relationship of other blood borne
diseases (Hepatitis B or Hepatitis C) associated with
intravenous drug usage in our seroprevalence groups.
HIV positive IVDUs showed a very high rate of Hepatitis
B or C infection, 76/144  (52.78%). In this group of 76
hepatitis and HIV dually infected individuals, 18/76
(23.68%) patients were HHV-8 infected. In contrast, in
the HIV positive Hepatitis B/C negative individuals (68/
144), only 7/68 (10.29%) were HHV-8 positive (Table 2).
Interestingly, all Hepatitis/HHV-8 positive individuals were
also HIV positive; there were no hepatitis B/C positive in
our group of 70 non IVDU HIV negative men (0%).
Discussion
To our knowledge this is the first study in an attempt to
determine the relationship between HHV-8 infection and
IVDUs in a Latin American country. In fact, there have
been no reports on the HHV-8 seroprevalence in a large
IVDU population. Lennette et al have studied a relatively
small group of American IVDUs and found the HHV-8
seroprevalence rate of about 23%6.  In contrast, Simpson
and coworkers studying 63 IVDUs from Edinburgh, found
an HHV-8 seroprevalence of only 3.17%7. Our study from
a large group of IVDUs from Argentina shows higher HHV-
8 seroprevalence rate than those reported by Simpson,
and similar to the one published by Lennette.
We have studied a group of high risk individuals who
have provided us with the unique opportunity to assess
the HHV-8 blood transmission through needle sharing
practices.  This route of transmission has not been
evaluated and it is still controversial whether this route of
transmission can occur. A case of HHV-8 transmission
by blood transfusion was published recently8, but its
significance is uncertain in view of the fact that in some
areas of the world such as Italy and some African
countries, where there is a high rate of HHV-8 among
normal blood donors1, 9, 10.
We have found that the rate of HHV-8 infection in
HIV positive IVDUs was about three times as high as
compared to the non IVDU HIV negative individuals
(17.36% vs. 5.71%), suggesting that intravenous drug
usage is a risk for HHV-8 infection, and that blood
transmission through needle sharing is possible. The
5.71% may reflect the seroprevalence of HHV-8 in the
general heterosexual population in Buenos Aires, similar
to those found in the US2. Our results indicate that blood
exposure is an alternative route of HHV-8 transmission
and is in agreement with the report published by Mendez
and coworkers, who showed that most patients with
post-transplant KS were already infected with HHV-8
prior to transplantation11.  Those patients were exposed
to blood borne diseases throughout years of chronic
dialysis.  In contrast, the studies reported by Beral and
coworkers challenge this notion, contending that blood
transfusion does not appear to represent a risk for AIDS-
associated KS12.
When we analyzed the relationship of blood borne
diseases (Hepatitis B or C) associated with intravenous
drug usage in our groups, we found that HIV positive
IVDUs showed a very high rate of hepatitis B or C
infection, 52.77%. Infection by Hepatitis B/C in this group
correlated with an increased risk for HHV-8 infection. A
23.68% of the hepatitis infected HIV positive IVDUs where
infected by HHV-8 as compared to 10.29% of the hepatitis
negative HIV positive individuals. These data strongly
support the notion that individuals who shared
contaminated needles and acquired hepatitis B or C, can
also acquire HHV-8 infection by the same route. These
findings are provocative and suggest an alternative route
of transmission, which may not be as efficient as sexual
Table 2.– HHV-8 seroprevalence among Hepatitis B/C
positive, HIV positive IVDUs
HIV Positive HIV/HHV-8 Positive
Hepatitis B/C 76-144 (52.78)+ 18/76 (23.68)
Positive
Hepatitis B/C 68/144 (47.22) 07/68 (10.29)
Negative
+ Percent of seropositivity
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transmission, possibly due to the low viremia rate in HHV-
8 infected individuals, but may explain some of the distinct
geographical distributions of HHV-8 infection.
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El Laboratorio del Instituto de la Ciencia, Palacio Poggi, Bologna.
(Mujeres de ciencia en la Italia del siglo XVIII)
En el siglo XVIII la ciencia experimental constituía un ámbito de investigación con continuas
interacciones, que en el Instituto, propiciaban la continuidad del laboratorio. Los estudios sobre la
influencia del fluido eléctrico sobre el organismo animal y el uso terapéutico de la electricidad cono-
cieron un enorme desarrollo en la segunda mitad del siglo XVIII. En ese período, durante el papado
de Benedetto XIV, el Instituto de la Ciencia pudo adquirir numerosos instrumentos y aparatos para la
observación y la experimentación científica. Una serie de medidas legales del Papa permitieron enri-
quecer el patrimonio instrumental del Instituto. Entre los aparatos se encuentra un generador eléctri-
co con un globo de vidrio. La Universidad y el Instituto de la Ciencia no eran la única sede de inves-
tigación científica. El gabinete privado de Laura Bassi, única mujer profesora del Instituto, tenía
importantes visitantes y representó un punto de referencia para los investigadores jóvenes. Entre
estos estaban Felipe Fontana y Leopoldo Caldani los que, en el salón de Bassi y su marido Veratti,
desarrollaron muchos de los experimentos sobre la irritabilidad halleriana y la electricidad.
Extractado y traducido de Guida ai Musei di Palazzo Poggi, Sciencia e Arte. Bologna: Editrice
Compositori, 2001, pp 96-7
